AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
57,000
Employees57,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
57,000
Employees57,000

ABBV Key Statistics

Market cap
510.63B
Market cap510.63B
Price-Earnings ratio
79.93
Price-Earnings ratio79.93
Dividend yield
2.42%
Dividend yield2.42%
Average volume
5.63M
Average volume5.63M
High today
—
High today—
Low today
—
Low today—
Open price
$286.90
Open price$286.90
Volume
4.05K
Volume4.05K
52 Week high
$291.40
52 Week high$291.40
52 Week low
$190.75
52 Week low$190.75

Stock Snapshot

The current AbbVie(ABBV) stock price is $285.49, with a market capitalization of 510.63B. The stock trades at a price-to-earnings (P/E) ratio of 79.93 and offers a dividend yield of 2.42%.

On 2026-10-21, AbbVie(ABBV) stock opened at $286.90, reached a high of —, and a low of —.

AbbVie(ABBV) shares are trading with a volume of 4.05K, against a daily average of 5.63M.

During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $291.40 at its peak.

During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $291.40 at its peak.

ABBV News

24/7 Wall St. 12m
Forget Social Security: 5 High-Yield Stocks Retirees Are Buying Instead

Investing Forget Social Security: 5 High-Yield Stocks Retirees Are Buying Instead Social Security raises are locked to a government formula, but a growing numbe...

Forget Social Security: 5 High-Yield Stocks Retirees Are Buying Instead
TipRanks 56m
AbbVie reaches agreement with pCPA for Elahere

AbbVie (ABBV) is pleased to announce that negotiations with the pan-Canadian Pharmaceutical Alliance have successfully been completed for Elahere, and that a Le...

Barron's 6h
AbbVie Inc. Research & Ratings | ABBV - Barron's

...

AbbVie Inc. Research & Ratings | ABBV - Barron's

Analyst ratings

75%

of 32 ratings
Buy
75%
Hold
21.9%
Sell
3.1%

More ABBV News

Simply Wall St 14h
AbbVie Posts Fresh Crohn’s Remission Data Ahead Of Its Biggest ESMO Reveal

AbbVie (NYSE:ABBV) reported new clinical data for dual-targeting Crohn’s therapy ABBV-466, showing higher endoscopic remission rates than current monotherapies....

AbbVie Posts Fresh Crohn’s Remission Data Ahead Of Its Biggest ESMO Reveal
The Motley Fool 21h
Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio.

Kevin Warsh's Federal Open Market Committee (FOMC) has its next meeting on Oct. 28 to decide on a course of action for interest rates. It looks as if they aren'...

Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio.
TipRanks 1d
AbbVie, McLaren Racing announce partnership

AbbVie (ABBV) and McLaren Racing today announced a multi-year partnership naming AbbVie an Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 T...

TipRanks 2d
AbbVie reports ABBV-466 trial meets primary endpoint

AbbVie (ABBV) announced that its investigational ABBV-466, a dual-targeting therapy against IL-23 p19 and integrin a4ss7, demonstrated higher rates of endoscopi...

TipRanks 3d
AbbVie announces new, updated data from solid tumor portfolio at ESMO 2026

AbbVie (ABBV) announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology, ESMO...

TipRanks 3d
AbbVie presents 20 scientific abstracts from its IBD portfolio

AbbVie (ABBV) announced the presentation of 20 new scientific abstracts from its IBD portfolio at the 2026 United European Gastroenterology, UEG, Week, October...

The Motley Fool 4d
Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle

Not all high-yield dividend stocks are created equal. Some are genuine income compounders, while others are traps. And the current environment, with interest ra...

Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.